Literature DB >> 18753623

Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor.

Da-Wei Zhang1, Rita Garuti, Wan-Jin Tang, Jonathan C Cohen, Helen H Hobbs.   

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein that controls plasma LDL cholesterol levels by posttranslational regulation of the LDL receptor (LDLR). Previously, we showed that PCSK9 binds specifically to an EGF-like repeat (EGF-A) in LDLR and reroutes the receptor from endosomes to lysosomes rather than to the cell surface. Here, we defined the regions in LDLR and PCSK9 that are required for receptor degradation and examined the relationship between PCSK9 binding and LDLR conformation. Addition of PCSK9 to cultured hepatocytes promoted degradation of WT LDLR and of receptors lacking up to four ligand binding domains, EGF-B or the clustered O-linked sugar region. In contrast, LDLRs lacking the entire ligand binding domain or the beta-propeller domain failed to be degraded, although they bound and internalized PCSK9. Using gel filtration chromatography, we assessed the effects of PCSK9 binding on an acid-dependent conformational change that happens in the extracellular domain of the LDLR. Although PCSK9 prevented the reduction in hydrodynamic radius of the receptor that occurs at a reduced pH, the effect was not sufficient for LDLR degradation. A truncated version of PCSK9 containing the prodomain and the catalytic domain, but not the C-terminal domain, bound the receptor but did not stimulate LDLR degradation. Thus, domains in both the LDLR and PCSK9 that are not required for binding (or internalization) are essential for PCSK9-mediated degradation of the LDLR.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18753623      PMCID: PMC2526098          DOI: 10.1073/pnas.0806312105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Cooperation between fixed and low pH-inducible interfaces controls lipoprotein release by the LDL receptor.

Authors:  Natalia Beglova; Hyesung Jeon; Carl Fisher; Stephen C Blacklow
Journal:  Mol Cell       Date:  2004-10-22       Impact factor: 17.970

Review 2.  A receptor-mediated pathway for cholesterol homeostasis.

Authors:  M S Brown; J L Goldstein
Journal:  Science       Date:  1986-04-04       Impact factor: 47.728

3.  Domain map of the LDL receptor: sequence homology with the epidermal growth factor precursor.

Authors:  D W Russell; W J Schneider; T Yamamoto; K L Luskey; M S Brown; J L Goldstein
Journal:  Cell       Date:  1984-06       Impact factor: 41.582

4.  Receptor-mediated endocytosis of low-density lipoprotein in cultured cells.

Authors:  J L Goldstein; S K Basu; M S Brown
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

5.  The LDL receptor gene: a mosaic of exons shared with different proteins.

Authors:  T C Südhof; J L Goldstein; M S Brown; D W Russell
Journal:  Science       Date:  1985-05-17       Impact factor: 47.728

6.  Deletion of clustered O-linked carbohydrates does not impair function of low density lipoprotein receptor in transfected fibroblasts.

Authors:  C G Davis; A Elhammer; D W Russell; W J Schneider; S Kornfeld; M S Brown; J L Goldstein
Journal:  J Biol Chem       Date:  1986-02-25       Impact factor: 5.157

7.  Self-association of the low density lipoprotein receptor mediated by the cytoplasmic domain.

Authors:  I R van Driel; C G Davis; J L Goldstein; M S Brown
Journal:  J Biol Chem       Date:  1987-11-25       Impact factor: 5.157

8.  The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA.

Authors:  T Yamamoto; C G Davis; M S Brown; W J Schneider; M L Casey; J L Goldstein; D W Russell
Journal:  Cell       Date:  1984-11       Impact factor: 41.582

9.  Acid-dependent ligand dissociation and recycling of LDL receptor mediated by growth factor homology region.

Authors:  C G Davis; J L Goldstein; T C Südhof; R G Anderson; D W Russell; M S Brown
Journal:  Nature       Date:  1987 Apr 23-29       Impact factor: 49.962

10.  Immunologic cross-reactivity of the low density lipoprotein receptor from bovine adrenal cortex, human fibroblasts, canine liver and adrenal gland, and rat liver.

Authors:  U Beisiegel; T Kita; R G Anderson; W J Schneider; M S Brown; J L Goldstein
Journal:  J Biol Chem       Date:  1981-04-25       Impact factor: 5.157

View more
  75 in total

1.  Mapping the binding region on the low density lipoprotein receptor for blood coagulation factor VIII.

Authors:  James H Kurasawa; Svetlana A Shestopal; Elena Karnaukhova; Evi B Struble; Timothy K Lee; Andrey G Sarafanov
Journal:  J Biol Chem       Date:  2013-06-10       Impact factor: 5.157

Review 2.  Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.

Authors:  Nabil G Seidah; Annik Prat; Angela Pirillo; Alberico Luigi Catapano; Giuseppe Danilo Norata
Journal:  Cardiovasc Res       Date:  2019-03-01       Impact factor: 10.787

3.  APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo.

Authors:  Ting Fu; YangYang Guan; Junjie Xu; Yan Wang
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2017-05-09       Impact factor: 4.698

Review 4.  Cholesterol, the central lipid of mammalian cells.

Authors:  Frederick R Maxfield; Gerrit van Meer
Journal:  Curr Opin Cell Biol       Date:  2010-06-02       Impact factor: 8.382

Review 5.  The PCSK9 decade.

Authors:  Gilles Lambert; Barbara Sjouke; Benjamin Choque; John J P Kastelein; G Kees Hovingh
Journal:  J Lipid Res       Date:  2012-07-17       Impact factor: 5.922

6.  Isolation and characterization of the circulating truncated form of PCSK9.

Authors:  Bomie Han; Patrick I Eacho; Michael D Knierman; Jason S Troutt; Robert J Konrad; Xiaohong Yu; Krista M Schroeder
Journal:  J Lipid Res       Date:  2014-04-28       Impact factor: 5.922

7.  An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.

Authors:  Kévin Ly; Rachid Essalmani; Roxane Desjardins; Nabil G Seidah; Robert Day
Journal:  J Biol Chem       Date:  2016-10-07       Impact factor: 5.157

8.  Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9.

Authors:  Kévin Ly; Yascara Grisel Luna Saavedra; Maryssa Canuel; Sophie Routhier; Roxane Desjardins; Josée Hamelin; Janice Mayne; Claude Lazure; Nabil G Seidah; Robert Day
Journal:  J Biol Chem       Date:  2014-05-07       Impact factor: 5.157

9.  A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.

Authors:  Joyce C Y Chan; Derek E Piper; Qiong Cao; Dongming Liu; Chadwick King; Wei Wang; Jie Tang; Qiang Liu; Jared Higbee; Zhen Xia; Yongmei Di; Susan Shetterly; Ziva Arimura; Heather Salomonis; William G Romanow; Stephen T Thibault; Richard Zhang; Ping Cao; Xiao-Ping Yang; Timothy Yu; Mei Lu; Marc W Retter; Gayle Kwon; Kirk Henne; Oscar Pan; Mei-Mei Tsai; Bryna Fuchslocher; Evelyn Yang; Lei Zhou; Ki Jeong Lee; Mark Daris; Jackie Sheng; Yan Wang; Wenyan D Shen; Wen-Chen Yeh; Maurice Emery; Nigel P C Walker; Bei Shan; Margrit Schwarz; Simon M Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-14       Impact factor: 11.205

10.  A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo.

Authors:  Nidhi Gupta; Niels Fisker; Marie-Claude Asselin; Marie Lindholm; Christoph Rosenbohm; Henrik Ørum; Joacim Elmén; Nabil G Seidah; Ellen Marie Straarup
Journal:  PLoS One       Date:  2010-05-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.